These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 11861)
21. Opioid and non-opioid central cardiovascular effects of ketamine. Seth S; Mukherjee D; Choudhary AK; Sinha JN; Gurtu S Naunyn Schmiedebergs Arch Pharmacol; 1990 Nov; 342(5):535-8. PubMed ID: 1965327 [TBL] [Abstract][Full Text] [Related]
22. Dopamine-induced coronary effects in the dog heart attributed to beta- and alpha-adrenergic mechanisms. Rabloczky G; Kékesi V; Mader MR; Juhász-Nagy A Arch Int Pharmacodyn Ther; 1988; 293():109-26. PubMed ID: 2844127 [TBL] [Abstract][Full Text] [Related]
23. Interaction of cholecystokinin (CCK-33) and its C-terminal fragments: CCK-8 and CCK-4 with alpha- and beta-adrenoceptor agonists and antagonists in the cardiovascular system of rats. Part A. Wiśniewska RJ Pol J Pharmacol; 1998; 50(3):203-12. PubMed ID: 9861628 [TBL] [Abstract][Full Text] [Related]
24. The cardiovascular actions of dopamine and the effects of central and peripheral catecholaminergic receptor blocking drugs. Setler PE; Pendleton RG; Finlay E J Pharmacol Exp Ther; 1975 Mar; 192(3):702-12. PubMed ID: 1120964 [TBL] [Abstract][Full Text] [Related]
25. The role of the central nervous system in the cardiovascular responses to yohimbine. Lang WJ; Lambert GA; Rush ML Arch Int Pharmacodyn Ther; 1975 Sep; 217(1):57-67. PubMed ID: 242288 [TBL] [Abstract][Full Text] [Related]
26. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046. Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223 [TBL] [Abstract][Full Text] [Related]
27. Responses of the cardiovascular system of the rat to noradrenaline infusions and their modification by adrenoceptor blocking agents. Imms FJ; Neame RL; Powis DA Br J Pharmacol; 1977 May; 60(1):115-22. PubMed ID: 18245 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms underlying the cardiovascular effects of a labdenic diterpene isolated from Moldenhawera nutans in normotensive rats. Lahlou S; de Barros Correia CA; Vasconcelos Dos Santos M; David JM; David JP; Duarte GP; Magalhães PJ Vascul Pharmacol; 2007 Jan; 46(1):60-6. PubMed ID: 16875882 [TBL] [Abstract][Full Text] [Related]
29. Differential blood pressure responses to intracisternal clonidine, alpha-methyldopa, and 6-hydroxydopamine in conscious normotensive and spontaneously hypertensive rats. Head GA; de Jong W J Cardiovasc Pharmacol; 1986; 8(4):735-42. PubMed ID: 2427812 [TBL] [Abstract][Full Text] [Related]
30. Effect of ibopamine on diuresis and arterial blood pressure in anesthetized rats and its interactions with dopaminergic and alpha- and beta-adrenergic antagonists. Ferrini R; Miragoli G Arzneimittelforschung; 1986 Feb; 36(2A):323-6. PubMed ID: 2871844 [TBL] [Abstract][Full Text] [Related]
31. Evidence that a novel dopamine receptor agonist, RDS-127 [2-di-n-propylamino-4,7-dimethoxyindane] has some centrally mediated cardiovascular actions. Arnerić SP; Long JP J Pharm Pharmacol; 1984 May; 36(5):318-21. PubMed ID: 6145768 [TBL] [Abstract][Full Text] [Related]
32. Possible involvement of beta endorphin(1-31) and dynorphin(1-13) in the central hypotensive mechanism of action of alpha methyldopa. van Giersbergen PL; Wiegant VM; de Jong W Neuroendocrinology; 1989 Jan; 49(1):71-9. PubMed ID: 2566129 [TBL] [Abstract][Full Text] [Related]
33. Differential cardiovascular and neuroendocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor blockade. van Woerkens LJ; Boomsma F; Man in 't Veld AJ; Bevers MM; Verdouw PD Br J Pharmacol; 1992 Oct; 107(2):303-10. PubMed ID: 1330172 [TBL] [Abstract][Full Text] [Related]
34. Extremely long-acting antihypertensive effects of KF-4317, a alpha- and beta 1-adrenoceptor blocker. Kubo K; Ikeda J; Nakamura J; Nakamizo N Arch Int Pharmacodyn Ther; 1985 Sep; 277(1):140-60. PubMed ID: 2865934 [TBL] [Abstract][Full Text] [Related]
35. Comparison of centrally mediated hypotensive action of methyldopa and DOPA in cats. Torchiana ML; Lotti VJ; Clark CM; Stone CA Arch Int Pharmacodyn Ther; 1973 Sep; 205(1):103-13. PubMed ID: 4148405 [No Abstract] [Full Text] [Related]
36. Further characterization of the cardiovascular effects of the dopamine beta-hydroxylase inhibitor SK&F 102698 in conscious hypertensive rats. Ohlstein EH; Kruse LI; Ezekiel M; Willette RN J Pharmacol Exp Ther; 1988 Oct; 247(1):186-95. PubMed ID: 3050029 [TBL] [Abstract][Full Text] [Related]
38. Hypotensive effects of eugenosedin-A with serotonin, alpha- and beta-adrenoceptor antagonistic activities in spontaneously hypertensive and normotensive rats. Shen KP; Chiu CC; Chen SJ; Chen IJ; Wu BN Pharmacology; 2004 Jun; 71(2):91-101. PubMed ID: 15118348 [TBL] [Abstract][Full Text] [Related]
39. Mechanism of the tachycardia following systemic alpha-methyldopa administration in conscious rats. van der Maas ML; Head GA; de Jong W J Cardiovasc Pharmacol; 1986; 8(5):1014-9. PubMed ID: 2429074 [TBL] [Abstract][Full Text] [Related]
40. The role of the sympathetic nervous system in the cardiovascular effects of systemically administered gamma-aminobutyric acid. Vemulapalli S; Barletta M Arch Int Pharmacodyn Ther; 1984 Jan; 267(1):46-58. PubMed ID: 6144293 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]